Table 2.
4-Year Outcomes | No Trastuzumab (n = 116) |
Trastuzumab (n = 128) |
---|---|---|
% (95% CI) | % (95% CI) | |
Distant relapse-free survival | 97 (92–99) | 99 (95–100) |
Overall survival | 99 (94–100) | 99 (95–100) |
Ipsilateral invasive breast cancer recurrence | 3 (0.3–5.5) | 2 (0.2–5.5) |
Contralateral invasive breast cancer | 1 (1) | 0 |
Second primary invasive cancer (non-breast) | 3 (0.13–6.77) | 2 (−0.4 to 4.4) |
Abbreviation: CI = confidence interval.